Multivariate survival analysis showed that tumour expression of P4HA2 is a poor prognostic factor for tumour recurrence in patients treated with BCS independent of known other determinants of high risk DCIS including patient age, nuclear grade, tumour size, presence of comedo necrosis and RT in the model (HR = 2.3, 95% CI = 1.3–4.4; p = 0.007) (Table 2). This evidence concerns the gene P4HA2 and ductal breast carcinoma in situ.